Everything you need to know before the ASX opens
Good morning! Here’s everything you need to know, and some things you don’t, before the ASX flings open its doors and begins trading today.
Good morning! Here’s everything you need to know, and some things you don’t, before the ASX flings open its doors and begins trading today.
Dimerix has received a US$30m (~$48m) upfront payment from Amicus Therapeutics under a US licensing deal for its phase III candidate in rare kidney disease.
Trek Metals continues to make exploration strides at its Christmas Creek project in Western Australia.
With major regulatory hurdles cleared, production is within reach at Titanium Sands’ Mannar Island project.
Orthocell’s Striate+ lands in its next major market, Singapore, priming the company for further launches in the ASEAN region.
Race Oncology has been given ethics approval for a Phase I trial of RC220 bisantrene alone and in combination with doxorubicin in adult solid tumour patients.
ASX rises for a third day, Tesla drops 5%, copper hits 5-month high and UBS sees gold reaching US$3200.
SNX is zeroing in on drill targets at the Warrior gold project with the help of gravity and geochemical surveys.
Adisyn’s newest board member and founder of 2D Generation talks the big plans both company’s two have now they have joined forces.
Multiple copper targets have been identified by Antares Metals at the Conglomerate Creek prospect, part of the Mt Isa North asset in QLD.
The myelofibrosis drug landscape has become more crowded since Syntara decided to focus on the disease in 2020, but the company is giving investors its best shot.
Trek Metals is ramping up drilling plans at Christmas Creek after spotting visible gold in drill chips.
Original URL: https://www.couriermail.com.au/business/stockhead/page/187